Instrument Inactif

Communiqués BioPharmX Corp OTC Bulletin Board

Actions

US09072X1019

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

04/04	Première demande d'extension de la période d'exclusivité approuvée pour Timber Pharmaceuticals, Inc.	CI
20/03	Approbation provisoire de la deuxième déclaration d'information révisée et du plan de Timber Pharmaceuticals, Inc.	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

LEO Pharma finalizes acquisition of key assets from Timber Pharmaceuticals	24/01	AQ
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market	29/11	AQ
Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American	28/11	AQ
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance	18/09/23	AQ
Timber Pharmaceuticals : Announces NYSE Acceptance of Plan to Regain Listing Compliance - Form 8-K	18/09/23	PU
TIMBER PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Timber Pharmaceuticals, Inc. - TMBR	29/08/23	BU
Timber Pharmaceuticals : Why Is Skillz (SKLZ) Stock Up 20% Today	23/08/23	PU
LEO Pharma Signs Agreement to Acquire Timber Pharmaceutical	22/08/23	AQ
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ESTE, PR, TMBR	21/08/23	PR
TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders	21/08/23	BU
Timber Pharmaceuticals to be Acquired by LEO Pharma	21/08/23	AQ
Timber Pharmaceuticals Discloses Communication From NYSE American	03/07/23	AQ
Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis	20/06/23	AQ
Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001	05/06/23	AQ
TIMBER PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	15/05/23	AQ
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results	15/05/23	AQ
Timber Pharmaceuticals : GAAP EPS of -$9.19, revenue of $0.08M misses by $0.72M	03/04/23	PU
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results	31/03/23	AQ
TIMBER PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	31/03/23	AQ
Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology	20/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués BioPharmX Corp OTC Bulletin Board

Actions

US09072X1019

Communiqués

Filtres